Similar articles

• Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry.

  Hira RS, Kennedy K, Nambi V, Jneid H, Alam M, Basra SS, Ho PM, Deswal A, Ballantyne CM, Petersen LA, Virani SS. Hira RS, et al. J Am Coll Cardiol. 2015 Jan 20;65(2):111-21. doi: 10.1016/j.jacc.2014.10.035. J Am Coll Cardiol. 2015. PMID: 25593051 Clinical Trial.
• Aspirin for primary prevention: do potential benefits outweigh the risks?

  Shakib S. Shakib S. Intern Med J. 2009 Jun;39(6):401-7. doi: 10.1111/j.1445-5994.2008.01888.x. Intern Med J. 2009. PMID: 19580619 Review.
• Should patients stop taking aspirin for primary prevention?

  Depta JP, Bhatt DL. Depta JP, et al. Cleve Clin J Med. 2015 Feb;82(2):91-6. doi: 10.3949/ccjm.82a.14114. Cleve Clin J Med. 2015. PMID: 25897597 Review. No abstract available.
• A Balanced View of Efficacy and Safety of Aspirin in Cardiovascular Diseases.

  Casado-Arroyo R, Lanas A, Brugada P. Casado-Arroyo R, et al. Curr Pharm Des. 2015;21(35):5101-7. doi: 10.2174/1381612821666150915110322. Curr Pharm Des. 2015. PMID: 26369681 Review.
• Aspirin for Primary Prevention.

  Richman IB, Owens DK. Richman IB, et al. Med Clin North Am. 2017 Jul;101(4):713-724. doi: 10.1016/j.mcna.2017.03.004. Med Clin North Am. 2017. PMID: 28577622 Review.